A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303

Clinical Cancer Research

Volumn 18, Issue 2, 2012, Pages 577-584

  Innocenti, Federico ^a   Owzar, Kouros ^b   Cox, Nancy L ^a   Evans, Patrick ^a   Kubo, Michiaki ^c   Zembutsu, Hitoshi ^c   Jiang, Chen ^b   Hollis, Donna ^b   Mushiroda, Taisei ^c   Li, Liang ^d   Friedman, Paula ^a   Wang, Liewei ^d   Glubb, Dylan ^a   Hurwitz, Herbert ^b   Giacomini, Kathleen M ^e   McLeod, Howard L ^f   Goldberg, Richard M ^g   Schilsky, Richard L ^a   Kindler, Hedy L ^a   Nakamura, Yusuke ^c   Ratain, Mark J ^a   more..

^a UNIVERSITY OF CHICAGO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c RIKEN   (Japan)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GEMCITABINE; INTERLEUKIN 17F; PLACEBO;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GERM LINE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AMINO ACID SUBSTITUTION; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERLEUKIN-17; KAPLAN-MEIER ESTIMATE; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84862908671     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1387     Document Type: Article

References (32)

1. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev 2009;18:1695-8.
2. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
3. Pliarchopoulou K, Pectasides D. Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev 2009;35:431-6.
4. Hartman M, Loy EY, Ku CS, Chia KS. Molecular epidemiology and its current clinical use in cancer management. Lancet Oncol 2010;11: 383-90.
5. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617-22.
6. Innocenti F, Cox NJ, Dolan ME. The use of genomic information to optimize cancer chemotherapy. Semin Oncol 2011;38:186-95.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
8. Iida A, Saito S, Sekine A, Takahashi A, Kamatani N, Nakamura Y. Japanese single nucleotide polymorphism database for 267 possible drug-related genes. Cancer Sci 2006;97:16-24. (Pubitemid 43257022)
9. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-9. (Pubitemid 44141658)
10. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006;34:W635-41. (Pubitemid 44529848)
11. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, et al. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 2009;4:e7765.
12. R Development Core Team. A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2009. [updated 2006 Apr 21; cited 2010 Jul 7]. Available from: http://www.R-project.org.
13. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
14. Kawaguchi M, Takahashi D, Hizawa N, Suzuki S, Matsukura S, Kokubu F, et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 2006;117:795-801.
15. Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE, et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001;167:4137-40. (Pubitemid 32954284)
16. Xie Y, Sheng W, Xiang J, Ye Z, Yang J. Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis. Cancer Invest 2010;28:598-607.
17. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. Genetic polymorphisms of molecules associated with inflammation and immune response in Japanese subjects with functional dyspepsia. Int J Mol Med 2007;20:717-23.
18. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol 2008;28:44-9.
19. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003;2:8.
20. Del Mare S, Salah Z, Aqeilan RI. WWOX: its genomics, partners, and functions. J Cell Biochem 2009;108:737-45.
21. Lange EM, Beebe-Dimmer JL, Ray AM, Zuhlke KA, Ellis J, Wang Y, et al. Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23. Prostate 2009;69:385-91.
22. Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007;110:3291-300. (Pubitemid 350106322)
23. Frullanti E, Galvan A, Falvella FS, Manenti G, Colombo F, Vannelli A, et al. Multiple genetic Loci modulate lung adenocarcinoma clinical staging. Clin Cancer Res 2011;17:2410-6.
24. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih Ie M, Buhler K, et al. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002;34:9-16. (Pubitemid 34260591)
25. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13. (Pubitemid 350134889)
26. Muerkoster S, Arlt A, Sipos B, Witt M, Grossmann M, Kloppel G, et al. Increased expression of the E3-ubiquitin ligase receptor subunit beta TRCP1 relates to constitutive nuclear factor-kappaB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 2005;65:1316-24. (Pubitemid 40270158)
27. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, et al. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 2008;14:8143-51.
28. Guo X, Xu B, Pandey S, Goessl E, Brown J, Armesilla AL, et al. Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett 2010;290:104-13.
29. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-7.
30. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26:4672-8.
31. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL, et al. SCAN: SNP and copy number annotation. Bioinformatics 2010;26:259-62.
32. Illumina. "TOP/BOT" strand and "A/B" allele: a guide to Illumina's method for determining strand and allele for the Golden Gate and Infinium assays [monograph on the Internet]. San Diego, CA: Illumina, Inc. [updated 2006 Jun 27; cited 2010 Dec 23]. Available from: http://www.illumina. com/documents/products/technotes/technote-topbot.pdf.